Calamos Advisors
ETON icon

Calamos Advisors’s Eton Pharmaceutcials ETON Stock Holding History

Calamos Advisors’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,634
Closed -$514K – 951
2025
Q3 		$514K Buy
+23,634
New +$392K ﹤0.01% 770

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Calamos Advisors's ETON Position: Q4 2025 in Review

Calamos Advisors sold out of Eton Pharmaceutcials (ETON) in Q4 2025, closing a stake of 23,634 shares — an estimated $514K sold.

Calamos Advisors first reported a position in ETON in Q3 2025 and held it in 1 quarter. The position peaked at $514K in Q3 2025. 104 funds tracked by Wall St. Rank hold ETON as of Q4 2025.

  • Calamos Advisors reported no remaining Eton Pharmaceutcials position as of Q4 2025 after selling out during the quarter.
  • Calamos Advisors sold 23,634 Eton Pharmaceutcials shares in Q4 2025, an estimated $514K.
  • Calamos Advisors first reported a position in Eton Pharmaceutcials in Q3 2025 and held it in 1 quarter.
  • Calamos Advisors's Eton Pharmaceutcials position peaked at $514K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q4 2025.

Based on Calamos Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.